Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 72Burkitt Lymphoma 43Neoplasm, Residual 18Leukemia 15Recurrence 14Lymphoma, Non-Hodgkin 8Leukemia, Biphenotypic, Acute 8Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoproliferative Disorders 6Lymphatic Diseases 5Lymphoma, Large B-Cell, Diffuse 4Lymphoma, B-Cell 4Lymphoma 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Leukemia, Lymphoid 4Immunoproliferative Disorders 4Neoplasms 3Blast Crisis 3Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Myeloid 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hematologic Neoplasms 2Down Syndrome 2Bites and Stings 2Sarcoma, Myeloid 1Philadelphia-Negative ALL 1Philadelphia Chromosome 1

Interventions

Cytarabine 6Vincristine 4Methotrexate 4Mercaptopurine 4pegaspargase 3merphos 3dexamethasone acetate 3dexamethasone 21-phosphate 3azathiopurine 3auricularum 3Thioguanine 3Dexamethasone 3Daunorubicin 3Cyclophosphamide 3Calcium Dobesilate 3Asparaginase 3prednylidene 2blinatumomab 2asparaginase erwinia chrysanthemi recombinant 2Prednisolone 2N,N-dicyclohexyl-isoborneol-10-sulfonamide 2Leucovorin 2Hydrocortisone 2Etoposide 2Doxorubicin 2hydrocortisone hemisuccinate 1deltacortene 1calaspargase pegol 1Spinal Puncture 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Down Syndrome × blinatumomab × Clear all
NCT03914625 2026-05-27

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
6,720 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT04546399 2025-09-10

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

National Cancer Institute (NCI)

Phase 2 Recruiting
461 enrolled
Lymphoid

Burkitt Lymphoma, Down Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡